Today’s Market Runner: What’s Ahead for Aptevo Therapeutics Inc After Making All-Time Low?

Today's Market Runner: What's Ahead for Aptevo Therapeutics Inc After Making All Time Low?

The stock of Aptevo Therapeutics Inc (NASDAQ:APVO) reached all time low today, Oct, 28 and still has $1.96 target or 11.00% below today’s $2.20 share price. This indicates more downside for the $42.37M company. This technical setup was reported by Barchart.com. If the $1.96 PT is reached, the company will be worth $4.66 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 142,240 shares traded hands. Aptevo Therapeutics Inc (NASDAQ:APVO) has risen 6.00% since September 28, 2016 and is uptrending. It has outperformed by 1.29% the S&P500.

According to Zacks Investment Research, “Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company’s platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.”

More notable recent Aptevo Therapeutics Inc (NASDAQ:APVO) news were published by: Businesswire.com which released: “Aptevo Therapeutics Completes Separation from Emergent BioSolutions” on August 01, 2016, also Quotes.Wsj.com with their article: “News Aptevo Therapeutics Inc.APVO” published on July 24, 2016, Seekingalpha.com published: “Aptevo Therapeutics: A Biotech Spinoff With Potential” on September 22, 2016. More interesting news about Aptevo Therapeutics Inc (NASDAQ:APVO) were released by: Globenewswire.com and their article: “Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 …” published on July 15, 2016 as well as Schaeffersresearch.com‘s news article titled: “Analyst Update: Aptevo Therapeutics Inc, PBF Energy Inc, and Cyberark Software Ltd” with publication date: September 09, 2016.

APVO Company Profile

Aptevo Therapeutics Inc. is a biotechnology company. The Firm focuses on oncology (cancer) and hematology (blood disease) therapeutics to manage patients’ lives. The Company’s segment is engaged in the discovery, development, commercialization and sale of sale oncology and hematology therapeutics. The Company’s core technology is the ADAPTIR (modular protein technology) platform. The Firm has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates MOR209/ES414, ES210, ES425 and otlertuzumab are built on its ADAPTIR (modular protein technology) platform. The technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The mechanisms of action for MOR209/ES414, ES210, ES425 and otlertuzumab include redirected T-cell cytotoxicity (RTCC), by which a therapeutic molecule brings T-cells into contact with tumor cells and trigger tumor killing, or targeted delivery of cytokines (or immune modulating protein) to diseased cells. The structural differences of ADAPTIR molecules over monoclonal antibodies allow for the development of new ADAPTIR immunotherapeutics that engage disease targets in a manner and produce a signaling response. It provides product candidate generation, validation and pre-clinical and clinical development using the ADAPTIR platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment